• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Exploring first-time GLP-1 prescriptions and new comorbidity diagnoses

Exploring first-time GLP-1 prescriptions and new comorbidity diagnoses

by Truveta Research | Dec 16, 2024 | Research, Research Insights

In partnership with Reuters, Truveta Research explored the percentage of patients who received a first-time diagnosis of type 2 diabetes, cardiovascular disease, or sleep apnea within 15 days of their first-time GLP-1 prescriptions. Truveta Research found that for...
Top reasons Truveta Data is the best real world data for studying diabetes

Top reasons Truveta Data is the best real world data for studying diabetes

by Truveta staff | Nov 16, 2023 | Data

In the world of healthcare, few conditions have seen as much transformation over the past decade as diabetes. With 37.3 million Americans living with diabetes, and a further 96 million in the prediabetes stage, it’s a life-altering health concern for nearly 40% of the...
SDOH factors like housing and financial stability are key to medication adherence

SDOH factors like housing and financial stability are key to medication adherence

by Truveta Research | Oct 17, 2023 | Research, Research Insights

Social drivers of health (SDOH), such as increased financial struggles and decreased social support, have been shown to be correlated with decreased medication adherence. In this study of patients with type 2 diabetes, we saw an increased rate of medication adherence...
Comparative effectiveness of SGLT2i vs. Metformin for first-line antidiabetic treatment

Comparative effectiveness of SGLT2i vs. Metformin for first-line antidiabetic treatment

by Truveta Research | May 9, 2023 | Research, Research Insights

This blog is an extension of our poster presented at ISPOR, titled Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin as First-Line Therapy in Type 2 Diabetes.   Individuals with type 2 diabetes mellitus (T2DM) have a higher risk of cardiovascular disease...

Share this


Recent posts

  • Truveta leads a new era in cancer research with the most complete, representative, and timely real-world data on all cancers
  • Top 5 takeaways from Truveta Symposium 2025
  • Women’s health: Pain medication remains rare for women receiving IUDs

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Get started

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Interested in learning more?

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice